Michael Zuehlsdorf

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Barbara Voith et al. · Clinical Pharmacology & Therapeutics · 2005 · 652 citations

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

Dagmar Kubitza, Michael Becka, Georg Wensing et al. · European Journal of Clinical Pharmacology · 2005 · 648 citations

Therapeutic Drug Monitoring, Pharmacology, Clinical Pharmacology +5

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf et al. · The Journal of Clinical Pharmacology · 2007 · 327 citations

Obesity, Thrombosis, Dose Adjustment +14

Effect of Food, an Antacid, and the H₂ Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf et al. · The Journal of Clinical Pharmacology · 2006 · 253 citations

Nutrition, Food Interaction Studies, Healthy Subjects +15

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · The Journal of Clinical Pharmacology · 2006 · 181 citations

Pharmacotherapy, Platelet Aggregation, Pharmacodynamic Modeling +18